Aristo Pharma Nordic ApS: Financial statements 2025
CVR: 32328768
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Aristo Pharma Nordic ApS (CVR 32328768) has filed annual accounts for 2025. In 2025, the company reported revenue of EUR 453,392 and a net result of EUR 21,589 compared with EUR 25,190 the year before. That is a decrease of 14.3% compared with the year before. The profit margin was 4.8%. Equity in the 2025 report amounted to EUR 184,874. The solvency ratio was 6.2%. The company had 3 employees in the financial year.
- Revenue
- EUR 453,392
- Gross Profit
- EUR 315,274
- Profit/Loss
- EUR 21,589
- Equity
- EUR 184,874
- Total Assets
- EUR 2,987,893
- Employees
- 3
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | 453K EUR | 315K EUR | 22K EUR | 185K EUR | 3 |
| 2024 | 529K EUR | 363K EUR | 25K EUR | 163K EUR | 3 |
| 2023 | - | 327K EUR | 26K EUR | 138K EUR | 3 |
| 2022 | - | 717K EUR | 52K EUR | 112K EUR | 5 |
| 2021 | - | 789K EUR | 45K EUR | 61K EUR | 7 |
Official annual report
How creditworthy is Aristo Pharma Nordic ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Aristo Pharma Nordic ApS has published its annual report for 2024. Revenue came to DKK 528,984, and the net result was DKK 25,190.
As of May 30, 2025, AIDER Godkendt Revisionsaktieselskab has stepped down as auditor of Aristo Pharma Nordic ApS.
About Aristo Pharma Nordic ApS
Aristo Pharma Nordic ApS is a Danish company of the type Anpartsselskab based in Skovlunde, founded in 2011. The company is registered under the industry Engroshandel med læge- og hospitalsartikler. The company was previously named AMNEAL NORDIC ApS and COPHARMA ApS. The management consists of John Hudson Kriwet. The board consists of John Hudson Kriwet (chair), Jannes Paul Beeskow and Robert Maciej Szymanski. The company is owned by Aristo Pharma GmbH. The company has 1 employee (2026). In 2025, the company reported revenue of EUR 453,392 and a net result of EUR 21,589 compared with EUR 25,190 the year before. Equity in the 2025 report amounted to EUR 184,874.